Conference Review

Trial updates in GA, MacTel type 2 and DME

Four ASRS abstracts look at ANX007, pegcetacoplan, encapsulated cell therapy and tarcocimab.

Update on mitochondrial stabilizers

Also from the Angiogenesis, Exudation, and Degeneration meeting, emerging treatments for nAMD and MacTel2, and a marker for anti-VEGF success in ROP.

AAO highlights: ILM peel in DR and more

Standout Retina Subspecialty Day 2022 talks include real-world faricimab and high-dose aflibercept results, and Protocol T outcomes.

Comparing techniques for RRD, MH

Prime cuts from ASRS also include a quick-response program for CRAO, and trials of agents for GA and mydriasis reversal.